免疫检查点抑制剂治疗肺癌的临床研究进展

Advance in clinical trials of immune checkpoint inhibitors for therapy of lung cancer

美国《科学》杂志将癌症免疫治疗列为2013年最重大的科学突破。在癌症免疫治疗中,抑制免疫检查点通路被认为是最有前景的治疗方式之一。过去的几年中,已经有多个抑制免疫检查点通路的单克隆抗体,ipilimumab,Nivolumab,MPDL3280A等已经进入临床试验。这些免疫检查点抑制剂在临床治疗肺癌中取得了一些突破性的进展。本文主要就免疫检查点抑制剂治疗肺癌的临床试验作一综述。

The American Journal Science has named cancer immune therapy as the last year＇s most groundbreaking scientific achievement. Blocking immune checkpoint pathways is regard as one of the most promising treatments in cancer immune therapy at now. Over the last several years, monoclonal antibodies, such as the anti-cytotoxic T-lymphocyte antigen-4 antibody （ipilimumab）, anti-programmed cell death-1 antibody （nivolumab）, and anti-programmed cell death-1 ligand antibody （MPDL3280A）, which inhibit immune-checkpoint pathways, have been tested in clinical trials. These immune-checkpoint inhibitors have made significant progress in lung cancer therapy. In this article, the clinical trials of immune checkpoint inhibitors for lung cancer therapy were reviewed.